

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jean Gosselin et al.
SERIAL NO.: UNASSIGNED EXAMINER: UNASSIGNED
FILED : HEREWITH ART UNIT: UNASSIGNED
FOR : AGENTS WITH LEUKOTRIENE B4-LIKE ANTI-VIRAL (DNA) AND
ANTI-NEOPLASTIC ACTIVITIES

STATEMENT

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Dear Sir:

Applicants submit herewith an Information Disclosure Statement and a Supplemental Information Disclosure Statement listing references **AA** through **BB** and **BC** through **BD** on the attached (2) Forms PTO-1449.

These IDS statements were submitted in parent application USSN **09/548,187** filed **April 13, 2000** with copies of all the listed references, except for AI - AM, AQ-AS, AY, AZ, AND BB, which were cited by the Examiner in an Information Disclosure Statement in connection with Application U.S. Serial No. 09/014,553 filed on January 28, 1998. Pursuant to 37 CFR § 1.98(d) copies of the Examiner cited references were not enclosed with the IDS submission for parent application USSN 09/548,187 filed on April 13, 2000. However, copies of the rest of the references listed on the Forms PTO-1449 were enclosed.

Applicants respectfully request that all copies of the cited references be transferred from the parent case to this continuation application filed herewith.

Respectfully submitted,


Veronica Mallon, Ph.D.
Agent for Applicant
Reg. No. 52,491

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
Dated: October 10, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gosselin et al.

SERIAL NO. : 09/548,187

EXAMINER: UNASSIGNED

DATE FILED : April 13, 2000

ART UNIT : 1614

FOR : AGENTS WITH LEUKOTRIENE B₄-LIKE ANTIVIRAL (RNA)
AND ANTI-NEOPLASTIC AGENTS

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on August 21, 2000.

Alexandra Huertas
(Name of depositor)

Alexandra Huertas 8/21/00
(Signature and Date)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

The publications (**AI - AM, AQ-AS, AY, AZ, BB**) listed on the attached Form PTO-1449 were cited by the Examiner in an Information Disclosure Statement in connection with Application U.S. Serial No. 09/014,553 filed on January 28, 1998. Pursuant to 37 CFR § 1.98(d), copies of the cited references are hereby not enclosed. However, copies of the rest of the references listed on the Form PTO-1449 are enclosed.

No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael A. Yamin", is written over a horizontal line.

Michael A. Yamin
Agent for Applicants
Registration No. 44,414

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800
E-mail: Yamin@kjiplaw.com

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY	2210-1-001CIP2
	SERIAL NO.	09/548,187
	APPLICANT	Gosselin et al.
	FILING DATE	April 13, 2000
	GROUP	1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	4,689,426	8/25/87	Sugiura et al	560	121	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Bevilacqua et al., PNAS USA, 1987, 84: 9238-9242
AC	Boyum A., Scand. J. Immunol., 1976, 5(5): 9
AD	Bray, R.A. et al., J. Immunol., 1986, 136: 1783
AE	Cecil's Textbook of Medicine, chapter 164, 19 th Edition, 1992.
AF	Cotran et al., J. Exp. Med., 1986, 164: 661-666.
AG	Devchand P.R. et al., Nature, 1996, 384: 39.
AH	Gagnon L. et al., Cell Immunol. 1987, 110: 243.

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY	2210-1-001CIP2
	SERIAL NO.	09/548,187
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Gosselin et al.
	FILING DATE	April 13, 2000
	GROUP	1614

AI	Hertting et al., "Formation and function of Eicosanoids in the CNS", Ann. N.Y. Aca. Sci. V. 559, 1989.
AJ	Kalmar et al., "Effect of Eicosanoids..." CA, 1986, 104: 219747.
AK	Lycke, "Virological aspects on herpesvirus infections" Medline 86151481, 1986.
AL	Marleau et al., Br. J. Pharmacol., 1994, 112: 654
AM	Marleau et al., J. Immunol., 1993, 150: 206.
AN	Matthews and Boehms, Rev Inf. Dis., 1988, 10, suppl. 3: 490
AO	Mehl et al., Antimicrob Agents Ch., 1980, 18: 269
AP	Miller G., Virology, 1990. pp 1921-1958
AQ	Murphy, "The molecular bio. of leukocyte chemoattractant receptors, 1994, CA 122:7234
AR	Nuhn et al., "Synergistic effect of a...", 1987, Derwent Abst. 87-29888
AS	Papp et al., "Binding of prostacyclin by plasma glycoproteins", 1985, CA104:82673.
AT	Reedman et al., Int. J. Cancer, 1973, 11: 499.
AU	Remington's Pharmaceutical Sciences, 16 th ed., 1980.
AV	Rola-Pleszczynski M. et al., Biochem Biophys. Res. Comm., 1982, 108: 1531.
AW	Rola-Pleszczynski M. et al., Biochem Biophys. Res. Comm., 1983, 113: 531.
AX	Rola-Pleszczynski M. et al., Prostaglandins Leukotrienes Med., 1984, 13: 113.
AY	Schechter et al., Characterization of a herpes virus..." MEDLINE 88274329, 1988.
AZ	Sinclair et al., "Eicosanoids and the liver", 1990, MEDLINE 92063107.
BA	Steinhart W.L. et al., Virology, 1976, 70: 241.
BB	Toshiki et al. "A patient in whom a PGE1...", 1995, JICST 02675404.

EXAMINER:	DATE CONSIDERED:
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Jean Gosselin *et al* EXAMINER : C. Chang
SERIAL NO. : 09/548,187 ART UNIT : 1625
FILED : April 13, 2000
FOR : AGENTS WITH LEUKOTRIENE B4-LIKE ANTIVIRAL ACTIVITIES
(as amended)


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The reference forwarded herewith is listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copy of References **BC** and **BD** listed on the attached Form PTO-1449.

No fee is believed due for the filing of this statement. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,



David A. Jackson
Agent for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.